Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €92.40 EUR
Change Today +1.55 / 1.71%
Volume 1.6K
SIE On Other Exchanges
Symbol
Exchange
EN Amsterdam
Xetra
OTC US
BrsaItaliana
Mexico
As of 10:04 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

siemens ag-reg (SIE) Snapshot

Open
€90.50
Previous Close
€90.85
Day High
€92.40
Day Low
€90.50
52 Week High
03/18/15 - €106.90
52 Week Low
10/16/14 - €80.40
Market Cap
81.4B
Average Volume 10 Days
970.1
EPS TTM
--
Shares Outstanding
881.0M
EX-Date
01/28/15
P/E TM
--
Dividend
€3.30
Dividend Yield
3.59%
Current Stock Chart for SIEMENS AG-REG (SIE)

siemens ag-reg (SIE) Details

Siemens Aktiengesellschaft operates as an electronics and electrical engineering company worldwide. The company’s Power and Gas segment offers gas and steam turbines, generators, compressors, and power plant solutions for gas-fired plants, as well as solutions for power plant I and C, electrical systems, and IT solutions. Its Wind Power and Renewables segment provides wind turbines; and implements turnkey projects for small hydropower plants. The company’s Power Generation Services segment offers service support, maintenance, repairs, replacements, modernizations, and upgrades for gas, steam, and wind turbines, as well as generators, power plants, and compressors; and remote monitoring and diagnostics services. Its Energy Management segment provides facilities and systems for the low-voltage and distribution power grid level, smart grid and energy automation solutions, power supply for industrial plants, and high-voltage transmission systems. The company’s Building Technologies segment offers fire safety, security, building automation, heating, ventilation, and air conditioning solutions, as well as energy management products and services. Its Mobility segment provides operation management systems for rail and road traffic with solutions for airport logistics, postal automation, and traction power supply, as well as rail vehicles for mass transit, regional, and long-distance service. The company’s Digital Factory segment offers integrated hardware, software, and technology-based services for manufacturing companies. Its Process Industries and Drives segment offers automation, drive technology, industrial software, and services. The company also provides commercial finance, insurance, asset management, project and structured finance, venture capital, and treasury services; and medical imaging, laboratory diagnostic, and healthcare IT solutions, as well as holds equity investments. Siemens Aktiengesellschaft was founded in 1847 and is headquartered in Munich, Germany.

343,000 Employees
Last Reported Date: 12/3/14
Founded in 1847

siemens ag-reg (SIE) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €3.2M
Chief Financial Officer, Executive Vice-Presi...
Total Annual Compensation: €1.7M
Chief Technology Officer, Executive Vice-Pres...
Total Annual Compensation: €1.7M
Member of the Managing Board
Total Annual Compensation: €1.7M
Member of Management Board
Total Annual Compensation: €1.7M
Compensation as of Fiscal Year 2014.

siemens ag-reg (SIE) Key Developments

Siemens Announces Executive Changes

The EU Commission has approved Siemens' acquisition of Dresser-Rand. Dresser-Rand's business - together with Siemens' compressor unit and the related service business - will form a new Dresser-Rand unit within Siemens Power and Gas Division with a primary focus on the oil and gas industry. Dresser-Rand's current CEO, Vincent Volpe will lead the business through the initial integration phase. Starting September 1, 2015, Christopher Rossi, 28-year veteran of Dresser-Rand, will take over the CEO position at the new business. Siemens manager Heribert Stumpf will serve as the unit's CFO.

Siemens Signs an Agreement with Elia Grid International to Develop High-Voltage Projects in the Europe, Middle East and Africa (EMEA) Region

Siemens has signed an agreement with Elia Grid International (EGI) to develop high-voltage projects in the Europe, Middle East and Africa (EMEA) region. The partners will collaborate to identify potential projects and clients, as well as on consulting and engineering the final implementation of the high-voltage infrastructure. Siemens and Elia Grid will also explore ways to improve and upgrade existing energy infrastructure. The companies intend to initially develop projects in countries south of the Sahara Desert.

Siemens and BioNTech AG Enter into Strategic Collaboration on Production of Personalized Cancer Vaccines

Siemens and BioNTech AG have entered into a strategic collaboration. BioNTech AG's subsidiaries, BioNTech RNA Pharmaceuticals GmbH and EUFETS GmbH, will work together with Siemens on the construction of a fully automated and digitalized production site to provide capacity for BioNTech's truly personalized cancer vaccines to serve worldwide markets. The cooperation will enable BioNTech to establish and integrate all necessary process and production steps for manufacturing its IVAC individualized vaccines at a larger scale. This strategic collaboration brings together each partner's specific competences in order to optimize automation and digitalization technology for a paperless, commercial-scale GMP (Good Manufacturing Practice) manufacturing of truly personalized medicines. The IVAC MUTANOME Immunotherapy approach is based on targeting the unique mutation signature of an individual patient's tumor. It is engineered on demand and administered as an individual treatment. IVAC MUTANOME is currently in a Phase I/IIa clinical trial for the treatment of malignant melanoma. Every cancer has an exclusive mutation signature resulting in a specific tumor antigen expression pattern, which makes every tumor absolutely unique. These tumor characteristics are used to generate treatments optimally attacking each tumor. The Individualized Cancer-immunotherapy (IVAC) platform uses tumor-specific information and tailors each patient's personalized RNA-based immunotherapy to activate the immune system of each patient to recognize, target, strike and combat his or her individual cancer. The concept allows for the design, manufacturing and distribution of the custom-made IVAC vaccines for each individual patient.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIE:IM €92.40 EUR +1.55

SIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Airbus Group SE €60.50 EUR +2.30
Comcast Corp $61.40 USD +1.26
Deutsche Telekom AG €15.57 EUR +0.07
Enel SpA €4.15 EUR +0.086
Boeing Co/The $140.58 USD +1.86
View Industry Companies
 

Industry Analysis

SIE

Industry Average

Valuation SIE Industry Range
Price/Earnings 13.8x
Price/Sales 1.1x
Price/Book 2.4x
Price/Cash Flow 10.9x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIEMENS AG-REG, please visit www.siemens.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.